XFUSION
18.5.2024 05:38:44 CEST | Business Wire | Press release
xFusion Digital Technologies Co., Ltd. (xFusion) dazzled attendees with its top-of-the-range computing products and solutions at the prestigious ISC High Performance 2024 event, hosted at the Congress Center Hamburg in Germany from May 13th to 15th. During the event, xFusion and fellow participants delved into the realms of AI and high performance computing (HPC) to explore their innovative applications and developmental trends, marking a significant convergence of minds and technologies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240516487957/en/
(Photo: xFusion)
Tab Tang , President of the Computing and Expansion at xFusion, delivered a keynote titled "Reinvent HPC in the Era of AI" during the Vendor Roadmap session on the 15th. He illuminated the pivotal role of smart computing in propelling industrial progress, highlighting the cooling challenges arising from high power and computing density, along with sustainability concerns. This necessitates clusters that are not only high-speed and low-latency but also highly reliable and stable. He also emphasized the transformative impact of AI on scientific endeavors, affirming xFusion's commitment to overcoming these challenges through pioneering software and hardware solutions. With a unified platform for both HPC and AI, xFusion aims to invigorate academic research and reshape the landscape of AI-driven HPC.
This year's ISC witnessed xFusion's spotlight on cutting-edge technologies like AI and HPC, presenting computing advancements characterized by openness, intelligence, eco-friendliness, and high-density. This compelling showcase drew attendees eager to delve deeper into these innovations.
At the event, xFusion proudly introduced FusionPoD for AI, a revolutionary rack-scale liquid-cooling cabinet poised to redefine computing paradigms. With its open architecture and support for diverse computing capabilities, FusionPoD for AI integrates groundbreaking architectural, software, and algorithmic innovations. It offers a fresh perspective by embracing multiple ecosystems, diversity, and low-carbon solutions to cater to the demanding requirements of AI large models and other HPC scenarios. This remarkable product delivers an unparalleled computing density of 64 GPUs and features a 100% liquid cooling native design with an impressively low pPUE of 1.06. xFusion also introduced the AI Space accelerator to both partners and customers, promising to expedite their AI application development and deployment.
xFusion stole the spotlight at ISC 2024 by showcasing its FusionOne HPC solution tailored for diverse HPC applications in education, scientific research, and manufacturing simulation. This state-of-the-art offering boasts adaptive characteristics, ensuring efficient, secure, reliable, and easily manageable operations. Notably, FusionOne HPC has already made waves with its deployment in the Weiming No. 2 Cluster at Peking University in 2023. This implementation has addressed the diverse needs of various disciplines, facilitating large-scale data processing and scientific computing while simultaneously reducing power consumption and fostering green research initiatives.
Beyond technological excellence, xFusion leads the charge in delivering comprehensive global business support through its dedicated team, bolstering remote O&M, cluster systems, and open architectural frameworks. Collaborating closely with partners, xFusion drives continuous innovation, fostering a thriving and sustainable HPC ecosystem. The current partnership with Bank Neo Commerce (BNC) in Indonesia marks a pivotal step in revolutionizing digital banking services. By offering agile, secure, and scalable digital infrastructure, xFusion empowers BNC to handle increasing transaction volumes and enhance customer interactions, fueling ongoing innovation and development in local digital banking services. FusionOnline, xFusion's remote intelligent O&M platform, is facilitating remote O&M in Europe, streamlining maintenance efforts while ensuring the long-term stability of user services.
Guided by the vision and mission of "Let Computing Serve You Better", xFusion has expanded its reach to over 100 countries and regions, cementing its status as a premier provider of computing infrastructures and services globally.
Looking to the future, xFusion remains optimistic about the potential of HPC to revolutionize industries and drive transformative innovation. In the era of AI, our ongoing contributions to the advancement of HPC underscore our commitment to shaping a brighter, more efficient, and interconnected world powered by our top-notch computing products and solutions.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240516487957/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom